AbCellera Biologics Inc.
NASDAQ:ABCLBiotechnology
-$0.02 today
- Market cap
- $3.60B
- Beta
- 1.20
- P/E (TTM)
- -11.4
- EPS (TTM)
- -$0.47
Volume 2.58M
Average 6.37M
ABCL Pre-Tax Margin
Income before tax as a percentage of revenue.
AbCellera Biologics Inc.NASDAQ: ABCL
Pre-Tax Margin · Q3 FY2026 · quarter ended Sep 2026
Pre-tax margin widens to -402.4%
Pre-tax margin was -402.4% in Q3 FY2026, up 365.5 pp from a year earlier. On a trailing-twelve-month basis it was -251.7%, up 328.4 pp year over year. Over 3 fiscal years it narrowed by 285.6 pp.
Context
- Pre-tax margin widened in 1 of the last 3 fiscal years.
Sources:Income StatementText generated from reported figures; not investment advice.
Pre-Tax Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -236.4%
- Year-over-year change
- +458.6pp
| Period | Period end | Pre-Tax Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -236.4% | +458.6pp |
| FY2024 | 2024-12-31 | -695.0% | -237.3pp |
| FY2023 | 2023-12-31 | -457.7% | -506.9pp |
| FY2022 | 2022-12-31 | 49.3% | -9.2pp |
| FY2021 | 2021-12-31 | 58.4% | — |
Pre-Tax Margin vs competitors
How ABCL compares with its peers on the latest reported figures
- ABCL's LTM Sep 2026 pre-tax margin of -251.7% is the 2nd highest of the 4 companies compared; the peer median is -698.6%.
- Its year-over-year change of +328.4 pp is the highest of 4, against a peer median of -12.5 pp.
- Over three fiscal years its change of -285.6 pp compares with a peer median of -1009.0 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | -211.5% | -12.5 pp | +259.8 pp | |
| LTM Sep 2026 | -251.7% | +328.4 pp | -285.6 pp | |
GENBGenerate Biomedicines, Inc. | FY2025 | -698.6% | +186.9 pp | — |
| LTM Mar 2026 | -6445.8% | -4214.8 pp | -2277.8 pp | |
| Peer median (excluding ABCL) | -698.6% | -12.5 pp | -1009.0 pp | |
Competitors are the stored peer set for ABCL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 375.2M | 485.42M | 38.03M | 28.83M | 75.13M |
| Cost of Revenue | 45.52M | 66.44M | 0 | 0 | 28.82M |
| Gross Profit | 329.69M | 418.99M | 38.03M | 28.83M | 46.31M |
| Gross Margin | 87.9% | 86.3% | 100.0% | 100.0% | 61.6% |
| Research & Development | 62.06M | 107.88M | 175.66M | 167.26M | 186.83M |
| Selling, General & Admin | 48.76M | 66.76M | 75.18M | 85.49M | 76.58M |
| Operating Expenses | 125.27M | 202.48M | 275.23M | 343.6M | 263.41M |
| Depreciation & Amortization | 17.25M | 33.1M | 30.89M | 97M | 28.82M |
| EBITDA | 239.15M | 260.17M | (192.16M) | (204.15M) | (148.77M) |
| EBITDA Margin | 63.7% | 53.6% | -505.3% | -708.0% | -198.0% |
| Operating Income | 204.41M | 216.51M | (237.21M) | (314.77M) | (217.1M) |
| Operating Margin | 54.5% | 44.6% | -623.8% | -1091.7% | -289.0% |
| Interest Income | 3.33M | 16.08M | 42.25M | 38.47M | 28.33M |
| Interest Expense | 5.23M | 4.05M | 0 | 0 | 0 |
| Other Income / Expenses | 14.74M | 22.59M | 63.18M | 114.37M | 39.51M |
| Income Before Tax | 219.15M | 239.1M | (174.03M) | (200.4M) | (177.6M) |
| Pre-Tax Margin | 58.4% | 49.3% | -457.7% | -695.0% | -236.4% |
| Income Tax Expense | 65.69M | 80.58M | (27.63M) | (37.54M) | (31.18M) |
| Net Income | 153.46M | 158.52M | (146.4M) | (162.86M) | (146.41M) |
| Net Margin | 40.9% | 32.7% | -385.0% | -564.8% | -194.9% |
| EPS (Basic) | 0.56 | 0.56 | (0.51) | (0.55) | (0.49) |
| EPS (Diluted) | 0.48 | 0.50 | (0.51) | (0.55) | (0.49) |
| Weighted Avg Shares | 275.76M | 285.06M | 289.17M | 294.33M | 298.71M |
| Weighted Avg Shares (Diluted) | 318.29M | 314.83M | 289.17M | 294.33M | 298.71M |
AbCellera Biologics Inc.
NASDAQ:ABCL
Intrinsic Alpha fair value
Locked
Current Price
$11.02
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.